Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

被引：0
|
作者：
Jang Ho Cho
Hyun Ae Jung
Se-Hoon Lee
Jin Seok Ahn
Myung-Ju Ahn
Keunchil Park
Jong-Mu Sun
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Pulmonary adenocarcinoma; Epidermal growth factor receptor; Programmed cell death-ligand 1; Predictive factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1341 / 1349
页数：8
相关论文
共 50 条
  • [41] The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
    Wen, Lu
    Tong, Fan
    Zhang, Ruiguang
    Chen, Lingjuan
    Huang, Yu
    Dong, Xiaorong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma
    Zhang, Bo
    Zhou, You Lang
    Chen, Xinming
    Wang, Ziheng
    Wang, Qiuhong
    Ju, Fei
    Ren, Shiqi
    Xu, Ran
    Xue, Qun
    Wu, Qiong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 68 : 131 - 136
  • [43] Impact of Clinicopathological Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients with Previously Treated Non-Small Cell Lung Cancer
    Jiang, T.
    Qiao, M.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2419
  • [44] Efficacy and safety profile of PD-1 and pdl-1 inhibitors in African American patients.
    Bari, Shahla
    Jain, Sanjay R.
    Pillai, Rathi Narayana
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
    Ken Masuda
    Hidehito Horinouchi
    Midori Tanaka
    Ryoko Higashiyama
    Yuki Shinno
    Jun Sato
    Yuji Matsumoto
    Yusuke Okuma
    Tatsuya Yoshida
    Yasushi Goto
    Noboru Yamamoto
    Yuichiro Ohe
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 245 - 251
  • [46] The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors
    Sun, Wei
    Yin, Xue
    Liu, Xiaomin
    Wei, Jianying
    Yu, Minghua
    Li, Wendong
    Ding, Xiaoyan
    Chen, Jinglong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [47] Clinical efficacy of HAIC (FOLFOX) combined with tyrosine kinase inhibitors plus PD-1 inhibitors vs. HAIC combined with bevacizumab plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma
    Zhu, Wenwen
    Zhang, Ningning
    Lu, Wei
    Zhang, Yiyan
    Liu, Kaipeng
    Liu, Huiru
    JOURNAL OF HEPATOLOGY, 2024, 80 : S454 - S455
  • [48] Expression of PD-1/PD-L1 in lung adenocarcinoma and its clinical significance
    Jian Li
    Yimin Chen
    Oncology and Translational Medicine, 2021, 7 (01) : 15 - 19
  • [49] Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients
    Nakamura, Yukiko
    Miyazaki, Kazuhito
    Aiko, Naoto
    Misumi, Yuki
    Agemi, Yoko
    Taniguchi, Yuri
    Ishi, Mari
    Shimokawa, Tsuneo
    Okamoto, Hiroaki
    Yamanaka, Takeharu
    ANTICANCER RESEARCH, 2020, 40 (02) : 923 - 928
  • [50] Efficacy analysis of regorafenib combined with PD-1 inhibitors in elderly patients with metastatic colorectal cancer
    Chen, Beibei
    Zhao, Huichen
    Huang, Jinxi
    Lv, Huifang
    Xu, Weifeng
    Nie, Caiyun
    Wang, Jianzheng
    Zhao, Jing
    He, Yunduan
    Wang, Saiqi
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345